Castel David, Pitaval Amandine, Debily Marie-Anne, Gidrol Xavier
CEA, DSV, DRR, Service de Génomique Fonctionnelle, 2 rue Gaston Crémieux-CP 22, 91057 Evry Cedex, France.
Drug Discov Today. 2006 Jul;11(13-14):616-22. doi: 10.1016/j.drudis.2006.05.015.
There is an increasing need for systematic cell-based assays in a high-throughput screening (HTS) format to analyze the phenotypic consequences of perturbing mammalian cells with drugs, genes, interfering RNA. Taking advantage of the recent progress in microtechnology, new cell microarrays are being developed and applied to a large range of issues in metazoan cells. This article compares different approaches and evaluates their potential use in the drug discovery process. Although still an emerging technology, cell microarrays hold great promise to optimize the efficiency:cost ratio in cell-based HTS.
在高通量筛选(HTS)模式下,对基于细胞的系统性检测的需求日益增加,以便分析药物、基因、干扰RNA对哺乳动物细胞造成干扰后的表型后果。利用微技术的最新进展,新型细胞微阵列正在被开发,并应用于后生动物细胞的一系列问题。本文比较了不同方法,并评估了它们在药物发现过程中的潜在用途。尽管细胞微阵列仍是一项新兴技术,但它在优化基于细胞的高通量筛选中的效率成本比方面具有巨大潜力。